CPH vs. CRON, GUD, TLRY, ACB, WEED, FIRE, EPI, OGI, ICC, and RIV
Should you be buying Cipher Pharmaceuticals stock or one of its competitors? The main competitors of Cipher Pharmaceuticals include Cronos Group (CRON), Knight Therapeutics (GUD), Tilray Brands (TLRY), Aurora Cannabis (ACB), Canopy Growth (WEED), Supreme Cannabis (FIRE), ESSA Pharma (EPI), Organigram (OGI), ICC Labs (ICC), and RIV Capital (RIV). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Cipher Pharmaceuticals vs.
Cronos Group (TSE:CRON) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.
Cipher Pharmaceuticals received 112 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 61.99% of users gave Cipher Pharmaceuticals an outperform vote while only 50.74% of users gave Cronos Group an outperform vote.
Cipher Pharmaceuticals has a net margin of 59.92% compared to Cronos Group's net margin of -42.65%. Cipher Pharmaceuticals' return on equity of 17.93% beat Cronos Group's return on equity.
Cipher Pharmaceuticals has a consensus target price of C$14.75, suggesting a potential upside of 18.19%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Cronos Group.
In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Cronos Group. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for Cronos Group. Cipher Pharmaceuticals' average media sentiment score of 0.67 beat Cronos Group's score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.
16.0% of Cronos Group shares are owned by institutional investors. Comparatively, 1.4% of Cipher Pharmaceuticals shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cipher Pharmaceuticals has lower revenue, but higher earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cronos Group has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Cipher Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
Summary
Cipher Pharmaceuticals beats Cronos Group on 16 of the 19 factors compared between the two stocks.
Get Cipher Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cipher Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:CPH) was last updated on 5/23/2025 by MarketBeat.com Staff